Compare NEOS S&P 500 High Income ETF (SPYI) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NEOS S&P 500 High Income ETF vs TransMedics Group Inc — how do they compare? NEOS S&P 500 High Income ETF trades at $54.2, while TransMedics Group Inc trades at $87.11 (market cap $3.10B). The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals.
| SPYI | TMDX | |
|---|---|---|
Sector | Income / Options Overlay | Technology |
52-Week High | $54.19 | $150.42 |
52-Week Low | $47.98 | $61.99 |
Market Cap | — | $3.10B |
Enterprise Value | — | $3.49B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPYI (NEOS S&P 500 High Income ETF) trades at $54.20, showing minimal daily movement with a 0.02% gain. The ETF employs an options overlay strategy on the S&P 500 to generate high monthly distributions, with recent dividends of $0.53-$0.54. Technical indicators show a bullish trend with strong moving average support, though RSI levels suggest potential overbought conditions. The fund's primary appeal is its ability to provide substantial income while maintaining S&P 500 exposure.
SPYI offers investors a unique income-generating approach through its options strategy, currently yielding approximately 12%. However, concerns exist about whether distributions represent true income versus return of capital. The fund's performance depends heavily on market volatility for option premium generation, creating both opportunity and risk. Investors should weigh the high yield against potential principal erosion in low-volatility environments.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NEOS S&P 500 High Income ETF
SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
